id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-P-0416-0004,FDA,FDA-2011-P-0416,"FDA/CDER to Lachman Consultant Services, Inc. - Responce Letter",Other,Letter(s),2011-11-17T05:00:00Z,2011,11,2011-12-06T05:00:00Z,,2011-12-06T19:44:15Z,,0,0,0900006480f7c7a2
FDA-2011-P-0416-0003,FDA,FDA-2011-P-0416,"Determinations that Product was Not Withdrawn from Sale for Reasons of Safety or Effectiveness: TRAVATAN (Travoprost Ophthalmic Solution), 0.004 percent",Notice,General Notice,2011-11-16T05:00:00Z,2011,11,2011-11-16T05:00:00Z,,2011-11-16T22:11:54Z,2011-29484,0,0,0900006480f6d68f
FDA-2011-P-0416-0001,FDA,FDA-2011-P-0416,"Lachman Consultant Services, Inc. - Citizen Petition",Other,Petition(s),2011-06-23T04:00:00Z,2011,6,2011-06-23T04:00:00Z,,2011-11-16T22:13:53Z,,0,0,0900006480e332f9
FDA-2011-P-0416-0002,FDA,FDA-2011-P-0416,"Acknowledgement Letter to Lachman Consultant Services, Inc.",Other,Acknowledgement Letter/Receipt,2011-06-23T04:00:00Z,2011,6,2011-06-23T04:00:00Z,,2013-07-27T23:54:16Z,,0,0,0900006480e332fb